Palbociclib
| Status | Pipeline |
| Development phase | Under development |
| Therapeutic cat. | Oncology |
| Polymorphic form | Crystal form A |
| CAS No. | 571190-30-2 |
| Reference Product | |
| Injectable Form | |
| EU DMF readiness |  |
| CEP | |
| CHINESE DMF | |
| JAPANESE DMF | |
| KOREAN DMF | |
| CANADIAN DMF | |
| CADIFA | |
| US DMF readiness | |
| OEB No. | 4 |
| Samples | available |
Drug description
Palbociclib is an oral medicine that is used to treat specific types of breast cancer in adults. It is used in combination with other cancer treatments, either aromatase inhibitor or fulvestrant, which one you use will depend on your clinical factors. It is a targeted therapy which blocks CDK4 and CDK6, which are enzymes in cells that are important for cell division. Blocking these proteins helps to slow down cells that are dividing, which slows down cancer growth.
Polpharma API
- Samples available
- Secured and high quality key intermediate sources
- Non-constrained PSD
- European API manufacturer
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).
